American Century Companies
YMAB

American Century Companies’s Y-mAbs Therapeutics YMAB Stock Holding History

American Century Companies’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-45,799
Closed -$745K – 2960
2024
Q1 		$745K Buy
45,799
+17,355
+61% +$234K ﹤0.01% 2270
2023
Q4 		$194K Buy
28,444
+6,683
+31% +$38.7K ﹤0.01% 2703
2023
Q3 		$119K Buy
21,761
+8,588
+65% +$50K ﹤0.01% 2697
2023
Q2 		$89.4K Buy
+13,173
New +$98.7K ﹤0.01% 2699

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

American Century Companies's YMAB Position: Q2 2024 in Review

American Century Companies sold out of Y-mAbs Therapeutics (YMAB) in Q2 2024, closing a stake of 45,799 shares — an estimated $745K sold.

American Century Companies first reported a position in YMAB in Q2 2023 and held it in 4 quarters. The position peaked at $745K in Q1 2024. 96 funds tracked by Wall St. Rank hold YMAB as of Q2 2024.

  • American Century Companies reported no remaining Y-mAbs Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American Century Companies sold 45,799 Y-mAbs Therapeutics shares in Q2 2024, an estimated $745K.
  • American Century Companies first reported a position in Y-mAbs Therapeutics in Q2 2023 and held it in 4 quarters.
  • American Century Companies's Y-mAbs Therapeutics position peaked at $745K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2024.

Based on American Century Companies's 13F filing for Q2 2024, filed 7 Aug 2024.